Analysis of 13,966 patients across 158 National Cancer Institute (NCI) trials highlights that immune checkpoint inhibitor-induced diabetes (ICI-D) has an overall cumulative incidence of 0.52%.
The risk of ICI-D is significantly higher with combination immunotherapy (OR 2.68) compared to PD-1/PD-L1 monotherapy, whereas concurrent chemotherapy appears to reduce the risk (OR 0.38).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
